Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $169.89 USD
Change Today -1.25 / -0.73%
Volume 496.2K
RCPT On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

receptos inc (RCPT) Snapshot

Open
$170.30
Previous Close
$171.14
Day High
$174.36
Day Low
$169.00
52 Week High
04/1/15 - $203.25
52 Week Low
05/20/14 - $24.53
Market Cap
5.4B
Average Volume 10 Days
729.1K
EPS TTM
$-4.56
Shares Outstanding
31.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for RECEPTOS INC (RCPT)

receptos inc (RCPT) Related Businessweek News

No Related Businessweek News Found

receptos inc (RCPT) Details

Receptos, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in immune disorders. Its lead product includes ozanimod, an oral therapy that is in phase III studies for the treatment of relapsing multiple sclerosis; and is in phase II studies to treat ulcerative colitis and crohn’s disease. The company is also developing RPC4046, a monoclonal antibody, which is in phase II trials for the treatment of eosinophilic esophagitis, an allergic/immune-mediated disorder. In addition, it is involved in a research program for glucagon-like peptide-1 receptor small molecule positive allosteric modulators that is in preclinical studies for the treatment of Type 2 diabetes. The company was formerly known as Receptor Pharmaceuticals, Inc. and changed its name to Receptos, Inc. in May 2009. Receptos, Inc. was founded in 2008 and is headquartered in San Diego, California.

68 Employees
Last Reported Date: 03/2/15
Founded in 2008

receptos inc (RCPT) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $534.4K
Co-Founder and Chief Technology Officer
Total Annual Compensation: $317.0K
Co-Founder and Chief Scientific Officer
Total Annual Compensation: $317.0K
Chief Financial Officer
Total Annual Compensation: $386.8K
Chief Medical officer
Total Annual Compensation: $437.8K
Compensation as of Fiscal Year 2014.

receptos inc (RCPT) Key Developments

Receptos, Inc. Reports Positive Results for the Maintenance Period of the Phase 2 TOUCHSTONE Trial of Ozanimod in Ulcerative Colitis

Receptos, Inc. announced that the maintenance period of TOUCHSTONE, the Phase 2 trial of ozanimod (formerly RPC1063) in ulcerative colitis (UC), met all efficacy endpoints with statistical significance in patients on the 1 mg dose of ozanimod after 32 weeks of treatment. The overall safety and tolerability profile of ozanimod was consistent with the results of TOUCHSTONE's induction period and those observed in the RADIANCE Phase 2 trial in relapsing multiple sclerosis (RMS), and continues to support the potential for orally administered ozanimod to significantly improve the treatment paradigm for UC patients. This randomized, double-blind, placebo-controlled trial assessed the efficacy, safety and tolerability of two orally administered doses (0.5 mg and 1 mg) of ozanimod versus placebo in 199 patients with moderately-to-severely active UC across 57 sites in 13 countries. For the induction period, the trial met its primary efficacy and all secondary endpoints with statistical significance for patients on the 1 mg dose after 8 weeks of treatment. In the maintenance portion of the trial, 103 patients who had achieved clinical response at week 8 continued with treatment for an additional 24 weeks. The proportion of patients in clinical remission at week 32 as defined by the industry standard Mayo scoring criteria was statistically significant in favor of both the 1 mg group and the 0.5 mg group (p < 0.05) compared to placebo.

Receptos, Inc. Presents at 10th Annual Neurotech Investing & Partnering Conference, Apr-08-2015 01:30 PM

Receptos, Inc. Presents at 10th Annual Neurotech Investing & Partnering Conference, Apr-08-2015 01:30 PM. Venue: Hotel Nikko, 222 Mason Street, San Francisco, California, United States. Speakers: Robert Peach, Co-Founder and Chief Scientific Officer.

Receptos To Get Takeover Interest Amid Partnership Talks

Receptos, Inc. (NasdaqGS:RCPT) is seeking a development partner for its multiple sclerosis treatment. Receptos is in talks with takeover interest from potential buyer sources states. Receptos is in discussion with ten companies, led to the takeover interest, the people said. Receptos is working with an investment bank as it explores its options.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RCPT:US $169.89 USD -1.25

RCPT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RCPT.
View Industry Companies
 

Industry Analysis

RCPT

Industry Average

Valuation RCPT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 836.8x
Price/Book 8.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 801.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RECEPTOS INC, please visit www.receptos.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.